 

Active ingredient: Auranofin 

 

Form/Route: Capsules/Oral 

 

Recommended studies: 2 studies 

 

1. Type of study: Fasting 

Design: Single-dose, parallel design in-vivo 

Strength: 3 mg 

Subjects: Healthy males and nonpregnant females, general population. 

Additional Comments: It is permissible to administer more than one capsule (up to three 
3 mg capsules) for the study to obtain adequate blood concentrations of the analyte to be 
measured. 




___________________________________________________________________________ 

 

2. Type of study: Fed 

Design: Single-dose, parallel design in-vivo 

Strength: 3 mg 

Subjects: Healthy males and females, general population. 

Additional Comments: Please see comments above. 

 




 

Analytes to measure (in appropriate biological fluid): Gold in whole blood 

 

Bioequivalence based on (90% CI): Gold 

 

Waiver request of in-vivo testing: Not Applicable 

 

Dissolution test method and sampling times: 

 

Please note that a Dissolution Methods Database is available to the public at the OGD website 
at http://www.accessdata.fda.gov/scripts/cder/dissolution/. Please find the dissolution 
information for this product at this website. Please conduct comparative dissolution testing on 12 
dosage units each of all strengths of the test and reference products. Specifications will be 
determined upon review of the application. 


